Rutika A Kokate1,2, Pankaj Chaudhary1,2, Xiangle Sun3, Sanjay I Thamake1,2,4, Sayantan Maji1,2, Rahul Chib3, Jamboor K Vishwanatha1,2, Harlan P Jones1,2. 1. Department of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA. 2. Institute of Cancer Research, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA. 3. Department of Cell Biology & Immunology, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA. 4. RadioMedix Inc., 9701 Richmond Avenue, Suite 222, Houston, TX 77042, USA.
Abstract
BACKGROUND: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. MATERIALS & METHODS: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. RESULTS: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. CONCLUSION: Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.
BACKGROUND: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. MATERIALS & METHODS: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. RESULTS: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. CONCLUSION: Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.
Entities:
Keywords:
DCs; NP; breast cancer; cancer vaccines; dendritic cells; immunotherapy; nanoparticle
Authors: Rodney A Rosalia; Luis J Cruz; Suzanne van Duikeren; Angelino T Tromp; Ana L Silva; Wim Jiskoot; Tanja de Gruijl; Clemens Löwik; Jaap Oostendorp; Sjoerd H van der Burg; Ferry Ossendorp Journal: Biomaterials Date: 2014-11-26 Impact factor: 12.479
Authors: Bijun Zeng; Anton Pj Middelberg; Adrian Gemiarto; Kelli MacDonald; Alan G Baxter; Meghna Talekar; Davide Moi; Kirsteen M Tullett; Irina Caminschi; Mireille H Lahoud; Roberta Mazzieri; Riccardo Dolcetti; Ranjeny Thomas Journal: J Clin Invest Date: 2018-04-09 Impact factor: 14.808
Authors: Alba Navarro-Ocón; Jose L Blaya-Cánovas; Araceli López-Tejada; Isabel Blancas; Rosario M Sánchez-Martín; María J Garrido; Carmen Griñán-Lisón; Jesús Calahorra; Francisca E Cara; Francisco Ruiz-Cabello; Juan A Marchal; Natalia Aptsiauri; Sergio Granados-Principal Journal: Pharmaceutics Date: 2022-02-25 Impact factor: 6.321